Group 1: Nipah Virus Detection Products - Wanfu Biology announced the launch of "Nipah Virus Nucleic Acid Detection Kit (Fluorescent PCR Method)" to meet the demand for rapid and accurate testing [2] - Kehua Bio stated that its subsidiary has developed a Nipah virus detection kit to support key prevention and control points such as customs and disease control centers [3] - Zhijiang Biology emphasized the importance of early virus isolation and nucleic acid testing due to the non-specific symptoms in early-stage patients, offering a high-sensitivity detection kit [4] - Capbio has developed a Nipah virus detection kit, providing core technical support for global quarantine and disease control monitoring [4] - Shengxiang Biology offers a dual-platform solution for rapid and accurate detection of Nipah virus, with its detection kit already receiving EU CE certification [4] - Antu Biology provides rapid detection support through its fully automated nucleic acid purification and real-time fluorescent PCR analysis system [4] Group 2: Market Reactions and Clarifications - Some A-share companies clarified their positions, stating they do not have any business related to Nipah virus. Hualan Biological announced it has no vaccine products for Nipah virus [5] - Sely Medical confirmed it currently has no Nipah virus testing reagents or treatment drugs in reserve [6] - Other companies like Weixin Kang and CanSino also stated they do not have related products [7]

Core Viewpoint - The recent outbreak of Nipah virus in India has raised public concern, but experts believe it is unlikely to spread on a large scale like COVID-19 [1] Group 1: Company Developments - Multiple companies, including Antu Biology, Shuoshi Biology, Jinhao Pharmaceutical, Kaipu Biology, Zhijiang Biology, Zhongke Shengyi, Weiboxin Biology, and Shengke Yuan Biology, have developed nucleic acid testing reagents for Nipah virus and are actively supporting testing efforts [1] - There is reported procurement demand in relevant regions, although there have been no significant changes domestically; some key ports have a demand for reagent reserves [1] Group 2: Industry Insights - Experts, including Professor Jin Dongyan from the University of Hong Kong, suggest that Nipah virus is not a new virus and has caused small outbreaks with single-digit cases almost every year for the past two decades [1] - The current situation is not significantly different from previous years, and the virus has a low incidence of asymptomatic infections, allowing for effective control through isolation [1]

【导读】印度尼帕病毒疫情引关注，相关概念股大涨，多家公司紧急回应 据悉，尼帕病毒感染潜伏期为3至14天，初期症状与流感相似，易出现误诊。这也意味着，早期精准检 测不仅能为临床干预争取时间，也是落实国境检疫、疫情溯源的核心环节。 随着尼帕病毒疫情持续发酵，市场对病毒防治、体外诊断等相关概念股的关注明显升温。截至1月27日 收盘，相关板块个股集体走强，凯普生物、达安基因斩获两连板；拓新药业、利德曼、特一药业等个股 涨幅居前。 | 凯普生物 | 8.70 | 20.00% | 1.45 | | --- | --- | --- | --- | | 300639 | | | | | ■正米 (天2板 入气龙头- 激电人 2020年半年频型示公司目主研发的 | | | | | 新型冠状病毒(2019-nCaV)核酸检测试刊盒(艾光PCR法)以新型冠状 ... | | | | | 达安惠因 | 7.71 | 9.99% | 0.70 | | 002030 @ | | | | | ■更新 2天2板 人气息头三 周期人用 多种药毒检测服务 | | | | | 拓新药业 | | 34.37 7.98% | 2.54 | | 30 ...

智通财经记者 | 陈杨 智通财经编辑 | 许悦 日前，印度东部西孟加拉邦出现的尼帕病毒病疫情引发广泛关注。 据新华社1月26日援引外媒消息，当地有5例确诊病例，其中包括医护人员。近100人已被要求居家隔 离，感染者正在该邦首府加尔各答及周边医院接受治疗，其中一名患者病情危重。 另据央视新闻记者1月27日从国家疾控局了解到，此次印度尼帕病毒病疫情对中国产生的影响相对较 小。目前，中国尚未发现尼帕病毒病病例。但也存在一定境外输入风险，需加强防范。 实际上，尼帕病毒并非当下新发现的病毒。据中国疾控中心2021年发布的《尼帕病毒病预防控制技术指 南》（下称《技术指南》），1998年，马来西亚首次发生尼帕病毒病暴发疫情。1999年3月，马来西亚 病毒学家从来自尼帕村的患者样本中分离出该种病毒，命名为尼帕病毒。 正是因为尼帕病毒传播性不高，相应药物商业价值有限，当下尚无针对尼帕病毒的抗病毒药物和疫苗研 发出来、获批上市。《技术指南》仅提及，利巴韦林对治疗尼帕病毒脑炎可能有效。该药是一种临床上 常见的广谱抗病毒药物。 目前，全球尼帕病毒病疫情主要发生在南亚和东南亚国家。其自然宿主为果蝠，主要分布在南亚、东南 亚和澳大利亚。 ...

Group 1 - The Nipah virus outbreak in West Bengal, India has confirmed 5 cases with nearly 100 people under observation, prompting neighboring countries like Thailand and Nepal to enhance health screening for travelers from India [1] - The World Health Organization (WHO) classifies the Nipah virus as a high-priority regional threat due to its high mortality rate of 40%-70% and the absence of approved vaccines or treatments [4][11] - The research team from Wuhan Institute of Virology has published findings indicating that the oral nucleoside drug VV116 shows significant antiviral activity against the Nipah virus, providing new hope for treatment [2][8] Group 2 - VV116, developed by Wangshan Wangshui and Junshi Biosciences, has shown potential against various RNA viruses, including the Nipah virus, and has been approved for COVID-19 treatment in China and Uzbekistan [7][8] - Following the announcement of VV116's efficacy against the Nipah virus, shares of Wangshan Wangshui surged by 10.9%, reaching a new high since its listing in November 2025 [4][5] - The market response to the Nipah virus outbreak has led to significant stock price increases for several companies involved in diagnostic testing, with companies like Kaipu Biological and Da'an Gene reporting substantial gains [12][13]

【#多公司称已具备尼帕病毒检测能力#】印度尼帕病毒疫情受到关注的同时，除博晖创新，凯普生物 （300639.SZ）、安图生物（603658.SH）等多家A股上市公司也在近日表示已掌握尼帕病毒检测技术或 研发出相关产品，但尚未形成营收规模。[话筒]安图生物向表示，印度相关疫情仍处初期阶段，没有办 法估计对公司尼帕病毒检测产品的需求，"印度市场我们也有做，但是我们海外的体量相对还是比较小 的。"[话筒]凯普生物指出，该病毒此前就有出现过，公司具备对其检测的技术能力，但目前并未商业 化，非紧急情况下推动其落地仍需一定时间。 来源：@21世纪经济报道微博 ...

Core Viewpoint - The article highlights the outbreak of Nipah virus in West Bengal, India, and emphasizes the critical role of rapid and accurate testing in epidemic prevention and monitoring, given the virus's high mortality rate of 40%-75% and the absence of effective vaccines or treatments [3]. Group 1: Industry Response - Companies such as Capbio, Shuoshi Bio, and Zhongke Shengyi have quickly responded to the Nipah virus outbreak by providing testing kits to aid in epidemic monitoring and prevention [4]. - The Nipah virus is classified as a newly emerging zoonotic virus, causing severe diseases characterized by encephalitis or respiratory illnesses in infected individuals [6]. Group 2: Product Offerings - Capbio offers a range of Nipah virus nucleic acid testing kits using fluorescence PCR methods, with various packaging options available [11]. - The testing kits include specifications for different sample types such as serum, plasma, throat swabs, whole blood, urine, and viral cultures, with a detection limit of 500 copies/mL and a report time of 70 minutes [18].

1月26日， 安图生物 涨5.98%，截至发稿，报39.54元/股，成交2.60亿元，换手率1.20%，总市值225.94 亿元。 资料显示，郑州安图生物工程股份有限公司位于河南省郑州经济技术开发区经开第十五大街199号，成 立日期1999年9月15日，上市日期2016年9月1日，公司主营业务涉及 体外诊断 试剂及仪器的研发、生产 和销售。主营业务收入构成为：试剂86.63%，仪器10.99%，其他1.40%，维保收入0.98%。 长江旭日混合A（021015）基金经理为施展。 截至发稿，施展累计任职时间4年30天，现任基金资产总规模8.02亿元，任职期间最佳基金回报 53.53%，任职期间最差基金回报48.76%。 从基金十大重仓股角度 数据显示，长江资管旗下1只基金重仓安图生物。长江旭日混合A（021015）四季度持有股数7.1万股， 占基金净值比例为2.47%，位居第十大重仓股。根据测算，今日浮盈赚取约15.83万元。 长江旭日混合A（021015）成立日期2024年7月24日，最新规模7245.04万。今年以来收益7.47%，同类 排名3499/9003；近一年收益29.07%，同类排名4600/81 ...

转自：智通财经 智通财经1月26日讯（记者 卢阿峰 何凡）近日，印度东部西孟加拉邦尼帕病毒疫情持续发酵。当地已确 诊5例感染病例，其中包括医护人员，近百人被要求居家隔离。叠加该病毒40%以上的高致死率，以及 目前尚无特效疫苗和有效疗法的现实，引发全球公共卫生领域高度警惕。 据央视新闻及新华社报道，近期印度东部西孟加拉邦暴发尼帕病毒感染疫情。截至1月26日，当地已确 诊5例病例，其中包含多名医护人员。感染者目前集中在该邦首府加尔各答及周边医院接受治疗，另有1 名患者病情危重，近100人被要求居家隔离观察。 或受此消息刺激，今日A股流感、检测及疫苗相关概念股当日逆势躁动，多只个股批量涨停，板块热度 快速攀升。智通财经记者联系多家相关上市公司核实业务布局，企业回应呈现明显分化：部分检测企业 确认拥有相关产品但暂无印度订单，部分企业主动释放技术储备信号，亦有疫苗企业明确表示未涉足相 关领域，提示市场理性看待股价波动。 印度尼帕疫情再度引发关注 世界卫生组织等权威机构介绍，尼帕病毒是一种致命的人畜共患RNA病毒，主要由果蝠携带，可通过 被污染的食物传播给人类，也可发生人际传播。其显著特征在于致死率高，官方公布的死亡率在 ...

郑州安图生物工程股份有限公司为规避汇率波动风险，拟使用不超过8,900万美元的自有资金开展外汇 套期保值业务，交易品种包括远期结售汇、外汇掉期、外汇期权等，交易期限自董事会审议通过之日起 12个月内有效。公司已制定相关管理制度，明确业务以实际经营为基础，禁止投机交易，并采取多项风 险防控措施。该事项旨在降低汇兑损失，增强财务稳健性，符合公司发展需要。 截至2026年1月23日收盘，安图生物（603658）报收于37.31元，较上周的36.89元上涨1.14%。本周，安 图生物1月19日盘中最高价报37.39元。1月19日盘中最低价报36.61元。安图生物当前最新总市值213.2亿 元，在医疗器械板块市值排名10/127，在两市A股市值排名1012/5182。 本周关注点 公司公告汇总 安图生物第五届董事会第十次会议决议公告 郑州安图生物工程股份有限公司于2026年1月20日召开第五届董事会第十次会议，审议通过《关于开展 外汇套期保值业务的议案》和《关于向金融机构申请贷款的议案》。会议应到董事12名，实际参与表决 12名，所有议案均获全票通过。公司拟向金融机构申请不超过人民币15亿元的贷款，用于日常经营及发 展 ...